Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis
Julia Z. Adamska(Stanford University), William H. Robinson(Stanford University), Michelle S. Bloom(VA Palo Alto Health Care System), Keith M. Sullivan(Duke Medical Center), Zelda Z. Love(Stanford University), Lynette Keyes-Elstein(National Institute of Allergy and Infectious Diseases), Daniel E. Furst(University of California, Los Angeles), Richard A. Nash(Colorado Blood Cancer Institute), Leslie J. Crofford(Vanderbilt University Medical Center), Amin Zia(Stanford University), Peter A. McSweeney(Mesoblast (United States)), Beverly Welch(National Institute of Allergy and Infectious Diseases), Ashley Pinckney(National Institute of Allergy and Infectious Diseases), Ellen Goldmuntz(National Institute of Allergy and Infectious Diseases), Maureen D. Mayes(The University of Texas Health Science Center)
Cited by 15
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k